Lineage Cell Therapeutics Inc 2022 SR
The report is Lineage Cell Therapeutics' inaugural 2022 Corporate Sustainability Report, highlighting its commitment to regenerative medicine and ESG principles. Key achievements include advancing clinical programs like OpRegen in partnership with Roche and Genentech, and expanding its pipeline with new cell transplant programs. The company emphasizes diversity, with women representing 64% of the workforce and 33% of the board. Environmental efforts focus on reducing waste, water usage, and carbon footprint through efficient facility management. The report aligns with SASB standards and details initiatives in patient advocacy, employee well-being, and ethical governance.
Company: Lineage Cell Therapeutics Inc
Sector: Health Care
Country: United States
Year: 2022
Type: SR
Pages: 20
Lineage Cell Therapeutics Inc
Corporate Sustainability Report
The report is Lineage Cell Therapeutics' inaugural 2022 Corporate Sustainability Report, highlighting its commitment to regenerative medicine and ESG principles. Key achievements include advancing clinical programs like OpRegen in partnership with Roche and Genentech, and expanding its pipeline with new cell transplant programs. The company emphasizes diversity, with women representing 64% of the workforce and 33% of the board. Environmental efforts focus on reducing waste, water usage, and carbon footprint through efficient facility management. The report aligns with SASB standards and details initiatives in patient advocacy, employee well-being, and ethical governance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees